(Q44579640)

4 December 2017

title

Role of fidaxomicin for the treatment of Clostridium difficile infection (English)

1 reference

4 December 2017

main subject

Clostridium difficile

0 references

author name string

Paul Juang

series ordinal

1

1 reference

4 December 2017

Jennifer S Hardesty

series ordinal

2

1 reference

4 December 2017

publication date

1 October 2013

1 reference

Journal of Pharmacy Practice

4 December 2017

published in

1 reference

4 December 2017

volume

26

1 reference

4 December 2017

issue

5

1 reference

4 December 2017

page(s)

491-497

1 reference

Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

Burden of gastrointestinal disease in the United States: 2012 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

An epidemic, toxin gene-variant strain of Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

Meta-analysis to assess risk factors for recurrent Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

Treatment of Clostridium difficile-associated disease: old therapies and new strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

Efficacy of rifaximin and vancomycin combination therapy in a patient with refractory Clostridium difficile-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

Duodenal infusion of donor feces for recurrent Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

Fidaxomicin versus vancomycin for Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

In vitro activity of OPT-80 against Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

In vitro activities of OPT-80 and comparator drugs against intestinal bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

Fidaxomicin inhibits spore production in Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

Rifaximin: new therapeutic indication and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

Effects of inoculum, pH, and cations on the in vitro activity of fidaxomicin (OPT-80, PAR-101) against Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

Efficacy of primed infusions with high dose ranitidine and omeprazole to maintain high intragastric pH in patients with peptic ulcer bleeding: a prospective randomised controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

Fidaxomicin for Clostridium difficile-associated diarrhoea: epidemiological method for estimation of warranted price

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190013499526

21 January 2018

Identifiers

DOI

10.1177/0897190013499526

1 reference

4 December 2017

1 reference